Volvac® IB FitVolvac

® IB Fit & Volvac

® ND + IB MLV

FLEXIBILITY THAT

UNFOLDS NEW SOLUTIONS

Effective solution for the preventionof IB infections

Boehringer Ingelheim Vetmedica GmbH

Binger Straße 173

55216 Ingelheim am Rhein, Germany

Phone: +49 6132 144528

global.poultry@boehringer-ingelheim.com

DESCRIPTION

Volvac® IB Fit

Freeze-dried Modified Live Virus Vaccine, containing Infectious Bronchitis virus, Massachusetts serotype, replicated in SPF (Specific Pathogen Free) chicken embryos. Each dose contains a minimum titer of 103 EID

50

Volvac® ND + IB MLV

Freeze-dried Modified Live Virus Vaccine against Newcastle disease, LaSota strain and Infectious Bronchitis, Massachusetts serotype. Each dose contains a minimum titer of ND105.5 EID

50 and IB 103 EID

50

INDICATIONS

Recommended for the vaccination and revaccination of healthy chickens, as an aid in the prevention of Infectious Bronchitis (IB) and Newcastle disease (ND)

DOSE

For administration in the drinking water, coarse spray or eye drop routes

Presentations:10 x 1000 ds10 x 2000 ds10 x 5000 ds5 x10000 ds

Read instructions in full and follow directions carefully before using the vaccine

Design your vaccination program according to the frequency of outbreaks of the disease in your area and the needs of your birds

PRECAUTIONS

• Store at 2° to 7 °C out of sunlight• Use entire contents when bottle is first opened. • Burn this container and all unused contents• Read carefully all directions in the insert before vaccinating• Keep out of reach of children• Consult your veterinarian

Infectious bronchitis (IB) is a highly contagious viral disease of chickens of

all ages and types that can affect the respiratory, renal and reproductive

systems, causing significant economic losses and major welfare concerns.

BROILERS:

• Poor feed conversion

• Reduced weight gain

• Secondary infections

• Increased use of antibiotics

• Increased condemnation at slaughter

LAYERS AND BREEDERS:

• Drops in egg production

• Poor egg quality

• Infected young birds may turn into false layers

• Low hatchability in breeders

Signs of IB in affected birds include depression and respiratory signs such

as gasping, coughing and nasal discharge; when the kidneys are affected,

birds may also have increased water intake, scouring and wet litter. Besides,

the mortality rate will increase. The most severe clinical signs are seen in

chicks younger than 6 weeks of age.

The effective control of IB infections is only possible with the use of live and

inactivated vaccines. In general, live attenuated vaccines of the

Massachusetts serotype are used as the base for an effective control

program.

Early vaccination of all types of chicken is essential. In broilers, only live

attenuated vaccines are used, usually in the hatchery, by coarse spray.

Future breeders and layers will subsequently receive an inactivated vaccine

before onset of lay.

THE CONTROL OF VARIANT STRAINS:

• Controlling IB is challenging because new strains of the virus

(so called variants) continue to emerge.

• The development of a new vaccine for every important pathogenic

strain is unrealistic, time consuming and costly.

• Research demonstrates that a vaccination protocol, which features

vaccines of more than one serotype can provide broad protection

against a variety of IBV strains.

• Such an approach includes a live IB vaccine of the Massachusetts

serotype and vaccines based on a different (variant) serotype.

THE ROLE OF VACCINATION in the control of Infectious Bronchitis

INFECTIOUS BRONCHITIS: A persistent challenge for the Poultry industry

Volvac® IB Fit is an efficacious and safe tool for the control of infectious bronchitis in poultry

A study was carried out to compare the performance of Volvac® IB Fit in comparison to the leading competitor live attenuated Massachusetts type vaccine. The study was designed to compare the two vaccines in their ability to replicate and to protect commercial broilers against a homologous challenge with the virulent M41 IBV isolate.

In the first part of the study, tracheal swabs were taken from the vaccinated chickens and the negative control group at 0, 2, 4, 7, 10 and 14 days of age. They were tested using a quantitative IBV qRT-PCR in order to measure virus replication.

For the complete technical bulletin on this study refer to your BI representative

Graph 1. Percentage of qRT-PCR positive tracheal swabs post vaccination by eye

drop of commercial broilers at day of age with Volvac® IB Mass MLV and the

competitor live attenuated IB vaccine.

Graph 2. Average qRT-PCR log 10 virus titre in tracheal swabs post vaccination by eye

drop of commercial broilers at day of age with Volvac® IB Fit and the competitor live

attenuated IB vaccine.

0 2 4 7 10 14

70

60

50

40

30

20

10

0

Percentage of qRT-PCR positive tracheal swabs

%

Days post vaccination

Volvac® IB Fit

Competitor IB vaccine

Negative control

2.5

2.0

1.5

1.0

0.5

0.0

qRT-PCR average virus titre (log10)

10

log

EID

RT

-PC

R t

itre

Days post vaccination14

Volvac® IB Fit

Competitor IB vaccine

Negative control

107420

In the second part of the study, vaccinated chickens and the negative control group were challenged with the virulent M41 strain of the

Massachusetts serotype, at 30 and 44 days post vaccination. The challenge dates were selected in order to measure mid and long term

protection in the different groups.

Protection was assessed by means of the ciliostasis test.

Graph 3. Volvac® IB Fit protection after IB M41 challenge of commercial broilers vaccinated at day of age by

eye drop with and with competitor live attenuated IB vaccine.

At 30 days post vaccination

High High

Volvac® IB FitCompetitor IB

vaccine

At 44 days post vaccination

Ciliostasis Protection Score

High High

Protection: 50% Low 50%-80% Medium 80% High

Volvac® IB FitCompetitor IB

vaccine

Volvac® IB Fit resulted in

a better (faster) vaccine

“take” in comparison to

the group vaccinated

with the competitor

live attenuated IB

vaccine

Vaccination with Volvac® IB Fit resulted in a high level

of protection after homologous challenge with the

virulent M41 strain of the Massachusetts serotype at

both challenge dates.

The length of protection provided by Volvac® IB Fit is

long enough to cover for the average life

time/span fattening period of commercial

broilers.

Volvac® IB offers versatility that fits any vaccination scheme

A vaccination program featuring Volvac® IB Fit and a vaccine of the 793B type results in broad protection* against a wide variety of IBV strains belonging to different serotypes (IBV Q1, IBV Variant 2, IBV QX, IBV M41 and IBV 793B).

Additionally, vaccination with Volvac® IB fit resulted in a high level of protection against challenge with IBV Arkansas type.

*Based on the ciliostasis test.

Unchallenged / unvaccinated control

Challenged / unvaccinated control

Competitor IB Mass

Volvac® IB Mass

Competitor IB Mass + 793B type

Volvac® IB Mass + 793B type

Numberof birds

GroupVaccine age of application

1 day 14 day

Challengeat

28-29 days

Protectionbased on

CiliostasisScore

Protection: < 50% Low 50%-80% Medium > 80% High

For the complete technical bulletin on this study refer to your BI representative.

Volvac® IB Fit and Volvac® ND + IB MLV could be used in combination with

MLV variant vaccines to achieve broad protection and a higher ROI

A study was carried out in order to evaluate the performance of Volvac® IB Fit and Volvac® ND + IB MLV, used in a program that includes a live attenuated variant vaccine. For comparison, the leading competitor live attenuated Massachusetts type of vaccine was included.

The objective was to test the cross protection against important serotypes from different parts of the world, after using the broader vaccination program.

Commercial broilers were vaccinated by eye drop against IB following different vaccination schedules. The level of maternally derived antibodies at day of age was measured by means of the hemagglutination inhibition test.

At four weeks of age the birds were challenged by eye drop with 104EID50

:

• IBV Variant 2 (Middle East and Turkey) • IBV Q1 (China, Latin America, Middle East and Europe) • IBV QX (China, Europe, Middle East and Asia) • IBV Arkansas (North America)

The strains used (representing different important serotypes) were chosen because of their widespread geographical importance and the problems they cause in the field.

Moreover, homologous challenge setups were included to evaluate the presence of interference when administering combined vaccines.

Protection was assessed by means of the ciliostasis test.

None of the programs resulted in a negative effect in the vaccinated birds. The vaccination reaction was comparable in all vaccinated groups.

The results of the experiments after challenge with different IBV strains are shown in the following table:

IBV

Va

ria

nt

Q1

10

5

10

10

10

8

1

2

3

4

5

6

-

Q1

Q1

Q1

Q1

Q1

-

QX

QX

QX

QX

QX

NA

Low

High

High

High

High

-

-

793B type

793B type

-

-

Unchallenged / unvaccinated control

Challenged / unvaccinated control

Competitor IB Mass

Volvac® IB Mass

Competitor IB Mass + 793B type

Volvac® IB Mass + 793B type

1

2

3

4

5

6

10

10

10

10

10

8

-

-

793B type

793B type

-

-

-

Variant 2

Variant 2

Variant 2

Variant 2

Variant 2

NA

Low

High

High

High

High

IB

V V

ar

ian

t 2

IBV

Va

ria

nt

QX

-

-

793B type

793B type

-

-

NA

Low

Medium

Medium

Medium

High

10

5

10

10

10

8

Unchallenged / unvaccinated control

Challenged / unvaccinated control

Competitor IB Mass

Volvac® IB Mass

Competitor IB Mass + 793B type

Volvac® IB Mass + 793B type

1

2

3

4

5

6

IBV

M4

1 a

nd

79

3B

NA

High

High

High

High

10

7

7

10

10

Unvaccinated / unchallenged control

Volvac® IB Mass+793B type

Volvac® IB Mass+793B type

Volvac® ND + IB MLV+793B type

Volvac® ND + IB MLV+793B type

1

2

3

4

5

-

-

-

-

-

-

M41

793B

M41

793B

IBV

Ar

ka

ns

as

NA

Low

High

High

5

10

15

15

Unchallenged / unvaccinated control

Challenged / unvaccinated control

Competitor IB Mass

Volvac® IB Fit

1

2

3

4

-

-

-

-

-

Arkansas

Arkansas

Arkansas

FLEXIBILITY THAT UNFOLDS

NEW SOLUTIONS

Volvac® IB Fit

CONVENIENT

HEALTHIER birds withless respiratory

problems

NO INTERFERENCE with subsequent

respiratory vaccinations

FIT INTO ANY VACCINATION SCHEME:can be used as a tool in the

strategy to control IB variants

VERSATILE:can be used in combination with

our ND or other IB variant vaccines

LONG LASTING immunity

FAST TAKE

LESS USE of antibiotics

HIGHER PROFIT

SAFE

Volvac® IB Fit

Volvac® ND + IB MLV